Illumina preliminary Q4 revenue about $1.155 billion, up 5%; full-year 2025 revenue flat
Illumina released unaudited preliminary results for the fourth quarter and fiscal year 2025 ahead of a J.P. Morgan Healthcare Conference webcast on January 13, 2026. Fourth-quarter revenue rose 5% to about $1.155 billion, while full-year revenue was flat at about $4.34 billion. The company said the figures are subject to audit and adjustment, and full results are due February 5, 2026.
Key points
- Q4 2025 revenue of about $1.155 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)
- Q4 2025 ex-China revenue of about $1.100 billion, up 7% from Q4 2024
- Preliminary GAAP diluted EPS of $2.14 to $2.17 for Q4 and $5.42 to $5.45 for fiscal 2025; non-GAAP diluted EPS of $1.27 to $1.30 for Q4 and $4.76 to $4.79 for fiscal 2025
- Full fourth-quarter and fiscal 2025 results are scheduled after market close on February 5, 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.